Dade International increases Spectral Diagnostics holding:
This article was originally published in Clinica
Executive Summary
US diagnostics company Dade International will exercise its warrants to purchase additional shares in Canadian cardiac assay developer Spectral Diagnostics. This follows the US launch of Spectral's CK-MB/Myoglobin panel test earlier this year (see Clinica No 644, p 18). Dade will spend $2 million and increase its stake in Spectral to around 6%.